|drug2543||Nicotinamide riboside Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The objective of the study is to evaluate the efficacy of helmet NIV in reducing the duration of invasive mechanical ventilation in order to minimize ventilator needs during the COVID-19 pandemic.
Description: duration of mechanical ventilation via endotracheal tubeMeasure: ventilator days Time: up to 4 weeks
Description: number of days admitted to the ICUMeasure: Intensive care unit (ICU) length of stay Time: up to 6 weeks
Description: number of patients requiring endotracheal intubation after extubationMeasure: need for re-intubation Time: up to 6 weeks
Description: number of days spent in hospital during enrollment hospitalizationMeasure: hospital length of stay Time: up to 6 weeks
Description: death from any cause during hospitalization time of enrollmentMeasure: hospital mortality Time: up to 6 weeks
Description: death from any cause 90 day, 1yearMeasure: long term mortality Time: up to 1 year
Description: including ventilator associated pneumonia, GI hemorrhage, DVT/PE, sacral decubitus ulcer, delirium, ICU acquired weaknessMeasure: ICU related complications Time: up to 6 weeks
Description: measure the location (home, rehabilitation center, nursing home)Measure: discharge location Time: up to 90 days
Description: days alive and institution freeMeasure: health care utilization Time: up to 6 weeks
Description: ultrasound measurement at end expiration: enrollment, pre extubation, post extubationMeasure: diaphragm ultrasound thickness Time: up to 6 weeks
Description: ultrasound measurement at end expiration and inspiration to calculate thickening fractionMeasure: diaphragm thickening fraction Time: up to 6 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports